1-氯-7-硝基异喹啉 | 244219-94-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 1-氯-7-硝基异喹啉
• 中文别名: 5-硝基-1-氯异喹啉
• 英文名称: 1-chloro-7-nitroisoquinoline
• CAS: 244219-94-1
• 化学式: C₉H₅ClN₂O₂
• 分子量: 208.604
• InChiKey: HGIRABLPBGPANF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8℃，惰性气体

反应信息

• 作为反应物：
  描述：

  1-氯-7-硝基异喹啉 在 10% palladium on activated charcoal 、 氢气 作用下， 生成 1,7-异喹啉二胺
  参考文献：
  名称：

  In vitro efficacy of 7-benzylamino-1-isoquinolinamines against Plasmodium falciparum related to the efficacy of chalcones

  摘要：

  A series of 1,7-diaminoisoquinolinamines, that are expected to mediate antimalarial activity by the same mechanism employed by the chalcones, were produced. Six 7-benzylamino-1-isoquinolinamines were found to be submicromolar inhibitors in vitro of drug-resistant Plasmodium falciparum, with the best possessing activity comparable to chloroquine. Despite being developed from a lead that is a DHFR inhibitor, these compounds do not mediate their antimalarial effects by inhibition of DHFR. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2010.11.099
• 作为产物：
  描述：

  2-甲基-5-硝基苯甲酸甲酯 在 三氟乙酸 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 1-氯-7-硝基异喹啉
  参考文献：
  名称：

  Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors

  摘要：

  The design, synthesis and biological evaluation of a series of isoquinoline-based hydroxamic acid compounds as novel HDACs inhibitors were reported herein. A detailed SAR study showed most of the compounds displayed good to excellent inhibitory activities against HDAC1, 3, 6. The IC50 values of compound 10c against HDAC1, 3, 6 were 4.17 +/- 0.11 nM, 4.00 +/- 0.10 nM, 3.77 +/- 0.07 nM, respectively. Most of the compounds showed great anti-proliferative activities against RPMI 8226, HCT 116 and Hep G2 cells. The IC50 values of compounds 10a-h against RPMI 8226 cancer cell proliferation were all below 1 mu M. HCT 116 cell was sensitive to the compounds 10a, 10f-g and 18a with the IC50 values <0.3 mu M. The active compounds 10a-d did not show inhibitory activity against hERG channel. All these evidence indicated these compounds had great potential as HDACs inhibitors for the further development. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.06.071

文献信息

• Synthesis and antimalarial activity of 7-benzylamino-1-isoquinolinamines
  作者：Clare E. Gutteridge、Marshall M. Hoffman、Apurba K. Bhattacharjee、Lucia Gerena

  DOI：10.1002/jhet.5570440319

  日期：2007.5

  suggests that 7-benzylamino-1-isoquinolinamines should mediate antimalarial effects by a mechanism distinct from that employed by existing antimalarial drugs. A series of these compounds was prepared in seven synthetic steps, via reductive amination of 1,7-isoquinolinediamine. In vitro efficacy testing of the novel compounds against Plasmodium falciparum revealed them to be potent antimalarial agents.

  计算机模型表明7-苄基氨基-1-异喹啉胺应通过不同于现有抗疟药所采用的机制来介导抗疟作用。通过1,7-异喹啉二胺的还原胺化反应，在七个合成步骤中制备了一系列这些化合物。新型化合物对恶性疟原虫的体外功效测试表明，它们是有效的抗疟药。
• Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity
  申请人：Gaster Mary Laramie

  公开号：US20050239797A1

  公开（公告）日：2005-10-27

  The invention relates to novel isoquinoline and quinazoline derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of various disorders.

  本发明涉及具有药理活性的新异喹啉和喹唑啉衍生物，其制备方法，含有它们的组合物以及它们在治疗各种疾病中的应用。
• Amide derivatives and nociceptin antagonists
  申请人：Japan Tobacco Inc.

  公开号：US20030055087A1

  公开（公告）日：2003-03-20

  The present invention relates to a compound of the formula [1′] 1 wherein R 2 is lower alkyl optionally substituted by hydroxy, amino and the like, ring B is phenyl, thienyl and the like, E is a single bond, —O—, —S— and the like, ring G is aryl, heterocyclic group and the like, R 5 is halogen atom, hydroxy, lower alkyl optionally substituted by halogen atom etc., and the like, t is 0 or an integer of 1 to 5, when t is an integer of 2 to 5, each R 5 may be the same or different, m is 0 or an integer of 1 to 8, and n is 0 or an integer of 1 to 4, and a nociceptin antagonist containing compound [1′] as an active ingredient. The compound [1′] shows, due to nociceptin antagonistic action, analgesic effect against sharp pain such as postoperative pain and the like. The present invention also relates to the use of certain amide derivative inclusive of compound [1′] as a nociceptin antagonist or analgesic.

  本发明涉及一种化合物，其化学式为[1′]1，其中R2是低碳基，可选择性地被羟基、氨基等取代，环B是苯基、噻吩基等，E是单键，-O-，-S-等，环G是芳基、杂环基等，R5是卤素原子、羟基、低碳基，可选择性地被卤素原子等取代，t为0或1至5的整数，当t为2至5的整数时，每个R5可能相同也可能不同，m为0或1至8的整数，n为0或1至4的整数，以及一种含有化合物[1′]作为活性成分的镇痛剂。由于其镇痛剂作用，化合物[1′]对于术后疼痛等尖锐疼痛具有镇痛效果。本发明还涉及某些酰胺衍生物的使用，其中包括化合物[1′]作为镇痛剂或镇痛剂拮抗剂。
• AMIDE DERIVATIVES AND NOCICEPTIN ANTAGONISTS
  申请人：Japan Tobacco Inc.

  公开号：EP1072263A1

  公开（公告）日：2001-01-31

  The present invention relates to a compound of the formula [1' ] wherein R2 is lower alkyl optionally substituted by hydroxy, amino and the like, ring B is phenyl, thienyl and the like, E is a single bond, -O-,-S- and the like, ring G is aryl, heterocyclic group and the like, R5 is halogen atom, hydroxy, lower alkyl optionally substituted by halogen atom etc., and the like, t is 0 or an integer of 1 to 5, when t is an integer of 2 to 5, each R5 may be the same or different, m is 0 or an integer of 1 to 8, and n is 0 or an integer of 1 to 4, and a nociceptin antagonist containing compound [1' ] as an active ingredient The compound [1' ] shows, due to nociceptin antagonistic action, analgesic effect against sharp pain such as postoperative pain and the like. The present invention also relates to the use of certain amide derivative inclusive of compound [1' ] as a nociceptin antagonist or analgesic.

  本发明涉及一种式 [1' ]的化合物。 其中 R2 是任选被羟基、氨基等取代的低级烷基，环 B 是苯基、噻吩基等，E 是单键、-O-、-S- 等，环 G 是芳基、杂环基等，R5 是卤素原子、羟基、任选被卤素原子等取代的低级烷基，t 是 0 或 1 至 5 的整数，当 t 是 2 至 5 的整数时，每个 R5 可以是相同的、等，t 为 0 或 1 至 5 的整数，当 t 为 2 至 5 的整数时，每个 R5 可以相同或不同，m 为 0 或 1 至 8 的整数，n 为 0 或 1 至 4 的整数，以及含有化合物[1']作为活性成分的痛觉素拮抗剂。本发明还涉及包含化合物[1' ]的某些酰胺衍生物作为痛觉素拮抗剂或镇痛剂的用途。
• [EN] DIARYLHYDANTOIN DERIVATIVE, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF<br/>[FR] DÉRIVÉ DE DIARYLHYDANTOÏNE ET PROCÉDÉ DE PRÉPARATION, COMPOSITION PHARMACEUTIQUE ET UTILISATION CORRESPONDANTS
  申请人：SHANGHAI PHARMACEUTICALS HOLDING CO LTD

  公开号：WO2015018356A1

  公开（公告）日：2015-02-12

  本发明公开了二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用。本发明提供了一种如式I所示的二芳基乙内酰脲衍生物、其药学上可接受的盐、溶剂化物、代谢产物、立体异构体、互变异构体、多晶型物或其药物前体，本发明的二芳基乙内酰脲衍生物对于治疗雄激素受体相关疾病，特别是去势耐受型前列腺癌有着良好的效果。